As expected, AAS for 10 weeks resulted in myocardial hypertrophy, which led to an increase in the HW/BW; HW/TL; cardiomyocyte cross-sectional area; ANF/18S, BNP/18S, and Myh7/Myh6 mRNA levels; and plasma NT-ProBNP levels, which were also significantly suppressed by the QSYQ post-treatment (Supplementary Figures S2A–J) (p < 0.05). This evidence concerns the gene MYH6 and cardiac hypertrophy.